Metastatic Uveal Melanoma (MUM) Market Size, Share, Trends, Leading Companies, Emerging Therapies and Epidemiology Forecast

 Breaking News
  • No posts were found

Metastatic Uveal Melanoma (MUM) Market Size, Share, Trends, Leading Companies, Emerging Therapies and Epidemiology Forecast

February 08
12:16 2021
Metastatic Uveal Melanoma (MUM) Market Size, Share, Trends, Leading Companies, Emerging Therapies and Epidemiology Forecast

Delveinsight Business Research LLP

DelveInsight’s “Metastatic Uveal Melanoma (MUM) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Metastatic Uveal Melanoma (MUM), historical and forecasted epidemiology as well as the Metastatic Uveal Melanoma (MUM) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

According to the National Cancer Institute, Metastatic Uveal melanomas or ocular melanoma can arise in the anterior (iris) or the posterior (ciliary body or choroid) uveal tract. Iris melanomas have the best prognosis, whereas melanomas of the ciliary body have the least favourable prognosis. Most uveal tract melanomas originate in the choroid, and the iris is the least common. Melanomas of the choroid generally are more malignant. The typical choroidal melanoma is a brown, elevated, dome-shaped subretinal mass. The degree of pigmentation ranges from dark brown to totally amelanotic.

The exact underlying cause of uveal melanoma is unknown, but people with blue or green eyes have a higher incidence. It generally occurs when the DNA of the pigment cells of the eye develop errors. These errors cause the cells to multiply out of control. The mutated cells collect in or on the eye and form a melanoma.

The symptoms of Metastatic Uveal Melanoma (MUM) include decreased or blurry vision, a sensation of flashes or specks of dust in vision, growing dark spots on the iris, change in the shape of the pupil at the centre of the eye, loss of peripheral vision, etc.

 Get FREE sample copy at:

The Metastatic Uveal Melanoma (MUM) market report also covers emerging drugs, current treatment practices, Metastatic Uveal Melanoma (MUM) market share of the individual therapies, current and forecasted Metastatic Uveal Melanoma (MUM) Market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Metastatic Uveal Melanoma (MUM) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. 


 Metastatic Uveal Melanoma (MUM) Market


Metastatic Uveal Melanoma (MUM) Market Key Facts
As per the National Cancer Institute, the mean age-adjusted incidence of Uveal melanoma in the United States is approximately 4.3 new cases per million people, with no clear variation by latitude. Ocular melanoma rates are 8–10 times higher among whites compared with blacks.

Males have a higher incidence of Metastatic Uveal Melanoma (MUM) than females (4.9 vs. 3.7 per million). Uveal melanoma is diagnosed mostly at older ages, with a progressively rising, age-specific, incidence rate that peaks near the age of 70 years.

According to a study conducted by Terai et al. titled “Immunological aspect of the liver and metastatic uveal melanoma” highlighted that Uveal (eye) melanoma was the most common primary eye malignancy in adults. Despite optimal treatments for primary uveal melanoma, up to 50% of patients subsequently develop systemic metastasis, often in the liver. Once hepatic metastasis develops, the survival of patients was generally short, and currently available treatments failed to show meaningful improvement of survival.

Key Benefits of Metastatic Uveal Melanoma (MUM) Market Report

  • Metastatic Uveal Melanoma (MUM) market report provides an in-depth analysis of Metastatic Uveal Melanoma (MUM) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.

  • The Metastatic Uveal Melanoma (MUM) market report will help in developing business strategies by understanding the Metastatic Uveal Melanoma (MUM) Market trends & developments, key players and future market competition that will shape and drive the Metastatic Uveal Melanoma (MUM) market in the upcoming years.

  • The Metastatic Uveal Melanoma (MUM) market report covers Metastatic Uveal Melanoma (MUM) current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Metastatic Uveal Melanoma (MUM) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Metastatic Uveal Melanoma (MUM) Market
The Metastatic Uveal Melanoma (MUM) market size is expected to increase during the forecast period owing to the launch of upcoming therapies in the market.

The Metastatic Uveal Melanoma (MUM) market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Metastatic Uveal Melanoma (MUM) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. 

The report gives a thorough detail of Metastatic Uveal Melanoma (MUM) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

 Metastatic Uveal Melanoma (MUM) Epidemiology
The Metastatic Uveal Melanoma (MUM) epidemiology section covers insights about historical and current Metastatic Uveal Melanoma (MUM) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

 Metastatic Uveal Melanoma (MUM) Drugs Uptake and Key Market Players
The Metastatic Uveal Melanoma (MUM) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Uveal Melanoma (MUM) market or expected to get launched in the market during the study period. The analysis covers Metastatic Uveal Melanoma (MUM) market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Currently, no standard of care exists to guide management is in Metastatic Uveal Melanoma. In Uveal Melanoma the most common site of metastatic disease in the liver and a number of hepatic-directed therapies are available including surgery, radiation therapy, radiofrequency ablation, embolization, and laser therapy.

The Metastatic Uveal Melanoma (MUM) pipeline is quite robust with several products available in the developmental stage. As per clinical trial registries, there are several key players involved in the development of promising combination products

Some of the key Metastatic Uveal Melanoma (MUM) companies involved in the development of therapeutic products include:
Delcath Systems
Syndax Pharmaceuticals
BioMed Valley Discoveries
Bristol-Myers Squibb
Bellicum Pharmaceuticals
And many others.

Metastatic Uveal Melanoma (MUM) therapies covered:
Pembrolizumab + Entinostat
Nivolumab + Ipilimumab
And many more.

Table of Content

1. Key Insights

2. Executive Summary 

3. Metastatic Uveal Melanoma (MUM) Competitive Intelligence Analysis

4. Metastatic Uveal Melanoma (MUM) Market Overview at a Glance

5. Metastatic Uveal Melanoma (MUM) Disease Background and Overview

6. Metastatic Uveal Melanoma (MUM) Patient Journey

7. Metastatic Uveal Melanoma (MUM) Epidemiology and Patient Population

8. Metastatic Uveal Melanoma (MUM) Treatment Algorithm, Current Treatment, and Medical Practices

9. Metastatic Uveal Melanoma (MUM) Unmet Needs

10. Key Endpoints of Metastatic Uveal Melanoma (MUM) Treatment

11. Metastatic Uveal Melanoma (MUM) Marketed Products

12. Metastatic Uveal Melanoma (MUM) Emerging Therapies

13. Metastatic Uveal Melanoma (MUM) Seven Major Market Analysis

14. Attribute Analysis

15. Metastatic Uveal Melanoma (MUM) Market Outlook (7 major markets)

16. Metastatic Uveal Melanoma (MUM) Access and Reimbursement Overview

17. KOL Views on the Metastatic Uveal Melanoma (MUM) Market.

18. Metastatic Uveal Melanoma (MUM) Market Drivers

19. Metastatic Uveal Melanoma (MUM) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Related Reports
Metastatic Uveal Melanoma (MUM) Epidemiology Forecast 
DelveInsight’s Metastatic Uveal Melanoma (MUM) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Metastatic Uveal Melanoma (MUM) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Metastatic Uveal Melanoma (MUM) Pipeline Insights
Metastatic Uveal Melanoma (MUM) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Metastatic Uveal Melanoma (MUM) market.

 About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States